Sirio Pharma (300791) — Cash Flow Reinvestment Rate
Sirio Pharma (300791) has a Cash Flow Reinvestment Rate of 0.78x as of June 2023, reinvesting CN¥79.56 Million (capex CN¥59.65 Million plus investments CN¥19.92 Million) from operating cash flow of CN¥101.61 Million. See 300791 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Sirio Pharma Cash Flow Reinvestment Rate (2017–2024)
Historical reinvestment intensity for Sirio Pharma across 8 annual periods. For the full cash flow conversion analysis, see Sirio Pharma (300791) cash flow conversion.
Annual Cash Flow Reinvestment Rate for Sirio Pharma (2017–2024)
Year-by-year capital reinvestment analysis for Sirio Pharma. See 300791 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 1.31x | CN¥740.12 Million | CN¥566.97 Million | CN¥412.13 Million | ▼ -68.7% |
| 2023 | 4.17x | CN¥1.61 Billion | CN¥386.08 Million | CN¥451.70 Million | ▲ +90.5% |
| 2022 | 2.19x | CN¥973.69 Million | CN¥444.86 Million | CN¥293.69 Million | ▼ -2.0% |
| 2021 | 2.23x | CN¥762.68 Million | CN¥341.38 Million | CN¥524.68 Million | ▲ +72.8% |
| 2020 | 1.29x | CN¥413.14 Million | CN¥319.57 Million | CN¥223.14 Million | ▼ -49.8% |
| 2019 | 2.58x | CN¥596.90 Million | CN¥231.60 Million | CN¥166.90 Million | ▼ -29.4% |
| 2018 | 3.65x | CN¥669.32 Million | CN¥183.46 Million | CN¥239.32 Million | ▼ -69.5% |
| 2017 | 11.95x | CN¥589.82 Million | CN¥49.35 Million | CN¥159.82 Million | — |